Timolol with bimatoprost ocular preservative-free
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Eye drops containing timolol and bimatoprost preservative-free.
Elevated IOP in ocular hypertension when beta blocker alone insufficient
Elevated IOP in open-angle glaucoma when beta blocker alone is insufficient
Instil one drop into the affected eye(s) once daily, administered either in the morning or in the evening. Administer at the same time each day.
Additional Dosage Information
If a dose is missed, treatment should be continued with the next dose as planned. Do not exceed one drop in the affected eye(s) daily.
Children under 18 years
History of asthma
Second degree atrioventricular block
Severe chronic obstructive pulmonary disease
Sinoatrial exit block
Third degree atrioventricular block
Uncontrolled cardiac failure
Precautions and Warnings
History of allergies including anaphylaxis
Risk factors for cystoid macular oedema
Chronic obstructive pulmonary disease
First degree atrioventricular block
Ischaemic heart disease
Pseudophakia with torn posterior lens capsule
Severe peripheral circulatory disorder
Uncontrolled diabetes mellitus
Advise diabetic patients that hypoglycaemic symptoms may be reduced/altered
Control cardiac failure before starting treatment
May mask symptoms of hyperthyroidism
May unmask the symptoms of myasthenia gravis
Advise patient blurred vision may affect ability to drive/operate machinery
Some formulations may contain traces of silver - risk of hypersensitivity
Advise patient hair growth may occur on areas of skin repeatedly exposed
In combined therapy, administer eye products at least five minutes apart
To reduce systemic absorption compress lacrimal sac during administration
Monitor for changes to iris pigmentation regularly
Monitor patient with history of severe cardiac disease for signs of failure
Advise patient that some eye changes may be permanent
Beta blockers may reduce the response to adrenaline in anaphylaxis
Systemic absorption & adverse effects of systemic beta blockers may occur
Consider gradual withdrawal of treatment prior to general anaesthesia
Advise patient to avoid touching the eye/other surfaces with container tip
Before initiating treatment inform patient of possibility of eyelash growth
Before initiating treatment inform patient of risk of eyelid skin darkening
Before starting treatment inform patient of risk of increased iris pigment
Pregnancy and Lactation
Use bimatoprost and timolol eye drops with caution during pregnancy.
The manufacturer recommends this medication is not used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. At the time of writing there is limited human data available. Risks are unknown.
Animal studies show reproductive toxicity at high maternotoxic doses.
Malformative effects have not been shown in epidermiological studies, however an increased risk of intra uterine growth retardation has been linked to beta-blockers taken orally. Beta-blockade symptoms have also been observed in the neonate.
Animal studies show reproductive toxicity at doses much higher than would be used.
Bimatoprost and timolol eye drops is contraindicated during breastfeeding.
The manufacturer confirms that this medication should not be used during breastfeeding.
At the time of writing there is limited published experience concerning the use of bimatoprost and timolol eye drops during breastfeeding.
It is not know if bimatoprost is excreted in human breast milk. However, it is excreted in the milk of lactating rats.
Timolol is excreted in breast milk, however ophthalmic use should pose little risk to a breastfed infant.
Abnormal liver function tests
Blurred vision (transient)
Burning and stinging of the eyes
Choroidal detachment (following filtration surgery)
Congestive cardiac failure
Cystoid macular oedema
Decreased corneal sensitivity
Exacerbation of myasthenia gravis
Exacerbation of pre-existing asthma
Exacerbation of psoriasis
Increased iris pigmentation
Periorbital skin pigmentation
Reduced visual acuity
Sensation of foreign body in eye
Superficial punctate keratitis
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: October 2019.
Summary of Product Characteristics: Eyzeetan 0.3mg/ml + 5mg/ml eye drops, solution. Aspire Pharma Limited. January 2020.
Summary of Product Characteristics: Ganfort 0.3mg/ml + 5mg/ml eye drops, solution in single-dose container. Allergan Ltd. Revised July 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.